DEF6: A Protein Implicated in Cell Adhesion and Disease (G50619)

Target Name: DEF6

NCBI ID: G50619

DEF6

DEF6: A Protein Implicated in Cell Adhesion and Disease

DEF6 (Slat) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and muscle. It is a key regulator of cell adhesion and has been implicated in a number of cellular processes that are important for normal development and function. DEF6 has also been identified as a potential drug target and biomarker for a variety of diseases.

The protein DEF6 is composed of 1,942 amino acids and has a calculated molecular mass of 21.1 kDa. It is expressed in a variety of tissues, including the brain, pancreas, and muscle, and is highly expressed in the liver. It is a key regulator of cell adhesion, and is involved in the formation of tight junctions, which are a type of cell-cell adhesion that is important for the proper functioning of tissues.

DEF6 is also involved in a number of other cellular processes that are important for normal development and function. For example, it is involved in the regulation of cell proliferation, and has been shown to play a role in the development and progression of a variety of diseases, including cancer. It is also involved in the regulation of ion channels, which are responsible for the flow of electrical current through cells.

In addition to its role in cellular processes, DEF6 has also been identified as a potential drug target and biomarker for a variety of diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. It is also thought to be involved in the development of certain cancers, such as ovarian and prostate cancer.

The potential drug target for DEF6 is based on its role in cell adhesion and the regulation of ion channels. Drugs that target these processes, such as those that interfere with the formation of tight junctions or those that inhibit the flow of electrical current through cells, may be effective in treating a variety of diseases.

In addition to its potential as a drug target, DEF6 is also thought to be a potential biomarker for a variety of diseases. For example, it may be used as a biomarker for neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, as it is thought to be involved in the development and progression of these conditions. It may also be used as a biomarker for certain cancers, such as ovarian and prostate cancer, as it is thought to be involved in the development and progression of these conditions.

Overall, DEF6 is a protein that is involved in a number of important cellular processes and has been implicated in a variety of diseases. As a potential drug target and biomarker, DEF6 is a promising target for future research and treatment. Further studies are needed to fully understand its role in these processes and its potential as a therapeutic agent.

Protein Name: DEF6 Guanine Nucleotide Exchange Factor

Functions: Phosphatidylinositol 3,4,5-trisphosphate-dependent guanine nucleotide exchange factor (GEF) which plays a role in the activation of Rho GTPases RAC1, RhoA and CDC42 (PubMed:12651066, PubMed:15023524). Can regulate cell morphology in cooperation with activated RAC1 (By similarity). Involved in immune homeostasis by ensuring proper trafficking and availability of T-cell regulator CTLA-4 at T-cell surface (PubMed:31308374). Plays a role in Th2 (T helper cells) development and/or activation, perhaps by interfering with ZAP70 signaling (By similarity)

The "DEF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets